Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM.

N Engl J Med. 2002 Aug 15;347(7):481-7.

2.

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

Pardanani A, Tefferi A.

Blood. 2004 Oct 1;104(7):1931-9. Epub 2004 May 27. Review.

3.

Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.

Cross NC, Reiter A.

Acta Haematol. 2008;119(4):199-206. doi: 10.1159/000140631. Epub 2008 Jun 20. Review.

PMID:
18566537
4.
5.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD.

Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Review.

PMID:
11740803
6.

[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].

Usui N.

Rinsho Byori. 2004 Feb;52(2):136-44. Review. Japanese.

PMID:
15027317
7.
9.

ETV6 gene rearrangements in hematopoietic malignant disorders.

Wlodarska I, Mecucci C, Baens M, Marynen P, van den Berghe H.

Leuk Lymphoma. 1996 Oct;23(3-4):287-95. Review.

PMID:
9031109
10.

[Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].

Zhang XY, Liu TF, Li CW, Li QH, Zhu XF.

Zhonghua Er Ke Za Zhi. 2018 Jan 2;56(1):34-38. doi: 10.3760/cma.j.issn.0578-1310.2018.01.009. Review. Chinese.

PMID:
29342995
11.

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.

Kolb EA, Pan Q, Ladanyi M, Steinherz PG.

Cancer. 2003 Dec 15;98(12):2643-50. Review.

12.

Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.

Kantarjian HM, Talpaz M.

Semin Oncol. 2001 Oct;28(5 Suppl 17):9-18. Review.

PMID:
11740802
13.

Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: review of the literature.

Diamantopoulos PT, Athanasiadou A, Papakostas E, Gratsias N, Georgiou G, Mantzourani M, Andreopoulos G, Panagiotidis P, Aessopos A, Meletis J, Viniou N.

Anticancer Drugs. 2011 Oct;22(9):944-7. doi: 10.1097/CAD.0b013e3283486ca4. Review.

PMID:
21712707
14.

Tyrosine kinase fusion genes in chronic myeloproliferative diseases.

Cross NC, Reiter A.

Leukemia. 2002 Jul;16(7):1207-12. Review.

15.

Imatinib mesylate (STI571) for myeloid malignancies other than CML.

Krystal GW.

Leuk Res. 2004 May;28 Suppl 1:S53-9. Review.

PMID:
15036942
16.

Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.

Savage N, George TI, Gotlib J.

Int J Lab Hematol. 2013 Oct;35(5):491-500. doi: 10.1111/ijlh.12057. Epub 2013 Mar 13. Review.

PMID:
23489324
17.

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.

Pardanani A, Tefferi A.

Leuk Res. 2004 May;28 Suppl 1:S47-52. Review.

PMID:
15036941
18.

Myeloid neoplasms with eosinophilia.

Reiter A, Gotlib J.

Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27. Review.

19.

[The study of 4 cases of myeloid neoplasm with t (5;12) (q33;p13) and the literatures review].

Kou L, Pan J, Qiu H, Chen S, Cen J, Zhang J, Bai S, Wu C, Wu Y, Gong Y, Shen J.

Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):302-7. doi: 10.3760/cma.j.issn.0253-2727.2016.04.011. Review. Chinese.

PMID:
27093993
20.

PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Andrei M, Bandarchuk A, Abdelmalek C, Kundra A, Gotlieb V, Wang JC.

Am J Case Rep. 2017 Feb 17;18:173-180. Review.

Supplemental Content

Support Center